AstraZeneca inks $555 million gene-editing technology deal with Algen, FT reports

(Reuters) -AstraZeneca has signed a $555 million deal with a San Francisco-based biotech business Algen Biotechnologies, The Financial Times reported on Monday.

The agreement with Algen gives AstraZeneca exclusive rights to develop and commercialise therapies from the Crispr gene-editing technology, the report said.

Reuters could not immediately confirm the FT report.

(Reporting by Raechel Thankam Job in Bengaluru; Editing by Rashmi Aich)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
• Is the global equity rally broadening? UBS weighs in
• At least 13 Tunisians missing after migrant boat sinks off Tunisia, group says